164 related articles for article (PubMed ID: 38504180)
21. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].
Zhang CX; Wang HT; Zhang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):827-831. PubMed ID: 34105479
[TBL] [Abstract][Full Text] [Related]
23. The role of CD27-CD70 signaling in myocardial infarction and cardiac remodeling.
Li W; Zhang F; Ju C; Lv S; Huang K
Int J Cardiol; 2019 Mar; 278():210-216. PubMed ID: 30527529
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.
Pojero F; Casuccio A; Giambanco C; Bulati M; Buffa S; Di Bassiano F; Gervasi F; Caruso C; Colonna Romano G
Leuk Res; 2016 Oct; 49():51-9. PubMed ID: 27552680
[TBL] [Abstract][Full Text] [Related]
25. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
Dhodapkar KM; Cohen AD; Kaushal A; Garfall AL; Manalo RJ; Carr AR; McCachren SS; Stadtmauer EA; Lacey SF; Melenhorst JJ; June CH; Milone MC; Dhodapkar MV
Blood Cancer Discov; 2022 Nov; 3(6):490-501. PubMed ID: 36026513
[TBL] [Abstract][Full Text] [Related]
26. CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.
Ye C; Low BE; Wiles MV; Brusko TM; Serreze DV; Driver JP
J Immunol; 2020 Oct; 205(7):1763-1777. PubMed ID: 32868408
[TBL] [Abstract][Full Text] [Related]
27. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.
Izawa K; Martin E; Soudais C; Bruneau J; Boutboul D; Rodriguez R; Lenoir C; Hislop AD; Besson C; Touzot F; Picard C; Callebaut I; de Villartay JP; Moshous D; Fischer A; Latour S
J Exp Med; 2017 Jan; 214(1):73-89. PubMed ID: 28011863
[TBL] [Abstract][Full Text] [Related]
28. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
29. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
30. Increased CD8
Zhao S; Zhang Y; Huang G; Luo W; Li Y; Xiao Y; Zhou M; Li Y; Lai J; Li Y; Li B
Blood Cells Mol Dis; 2019 Jul; 77():34-42. PubMed ID: 30953940
[TBL] [Abstract][Full Text] [Related]
31. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
32. Plasma cell generation from B-lymphocytes via CD27/CD70 interaction.
Agematsu K; Hokibara S; Nagumo H; Shinozaki K; Yamada S; Komiyama A
Leuk Lymphoma; 1999 Oct; 35(3-4):219-25. PubMed ID: 10706444
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
34. Blockade of costimulatory CD27/CD70 pathway promotes corneal allograft survival.
Narimatsu A; Hattori T; Usui Y; Ueno H; Funaki T; Komatsu H; Nakagawa H; Akiba H; Goto H
Exp Eye Res; 2020 Oct; 199():108190. PubMed ID: 32798537
[TBL] [Abstract][Full Text] [Related]
35. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
36. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
37. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
38. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction.
Gong L; Luo J; Zhang Y; Yang Y; Li S; Fang X; Zhang B; Huang J; Chow LK; Chung D; Huang J; Huang C; Liu Q; Bai L; Tiu YC; Wu P; Wang Y; Tsao GS; Kwong DL; Lee AW; Dai W; Guan XY
Nat Commun; 2023 Apr; 14(1):1912. PubMed ID: 37024479
[TBL] [Abstract][Full Text] [Related]
39. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
Inaguma S; Ueki A; Lasota J; Komura M; Sheema AN; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Miettinen M; Takahashi S
J Pathol Clin Res; 2023 May; 9(3):195-207. PubMed ID: 36754859
[TBL] [Abstract][Full Text] [Related]
40. Lack of CD27 in myeloma delineates different presentation and outcome.
Moreau P; Robillard N; Jégo G; Pellat C; Le Gouill S; Thoumi S; Avet-Loiseau H; Harousseau JL; Bataille R
Br J Haematol; 2006 Jan; 132(2):168-70. PubMed ID: 16398651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
